A review was recently published in the Journal of Neurochemistry which acknowledged PD-MitoQUANT research funding. "α‐synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities" authored by a team consisting of Parvez Alam, Luc Bousset, Ronald Melki and Daniel E. Otzen appeared in the 29 June 2019 issue. Ronald and Luc are PD-MitoQUANT PIs from the Centre National de la Recherche Scientifique, the CNRS in France. Congratulations to all! DOI: 10.1111/jnc.14808 Download the open access paper here.
It's hard to believe we're halfway through our first year! Learn more about the team and the project in our first newsletter...
A few questions were posed to PI Prof Dr Donato (Dino) DiMonte to gain his views on his work in Parkinson research and PD-MitoQUANT, in general. Dino is a senior researcher and leads the Neurodegeneration and Neuroprotection in Parkinson’s Disease Group at the German Center for Neurodegenerative Diseases (DZNE). Please describe your day to day work. It is difficult to describe a “typical” day of work. Most of the time, our working schedule involves specific tasks that vary from day to day and often have specific deadlines. For example, there are deadlines to apply for research grants, to complete research reports, to submit and review manuscripts and to perform administrative and educational duties. There are also commitments that, albeit quite regular, may not be part of a “daily” routine. These include attendance at research seminars, conference calls with research collaborators and participation in scientific meetings organized “in house” or requiring [...]
The 5th World Parkinson Congress (WPC) was held in Kyoto, Japan from June 4– 7, 2019. More than 3,000 people from more than 60 countries attended the meeting. At this meeting, Dr Ronald Melki of the Centre National de la Recherche Scientifique (CNRS) and PD-MitoQUANT PI presented: "What is alpha-synuclein- The biology". Through Ronald's talk, PD-MitoQUANT funding was acknowledged. Dr Ronald Melki, CNRS at WPC 2019 The WPC 2019 hosted an international, interdisciplinary forum showcasing the most important developments in the world of Parkinson's. As medical advances continue to accelerate, the goal of the WPC is to advance an all-encompassing approach to the treatment of Parkinson’s by bringing together the full spectrum of those who serve the Parkinson’s community. These will include representatives of professional medical and scientific organizations; nurses and rehabilitation professionals; voluntary, lay, and patient services organizations; the pharmaceutical industry; and the research and health services [...]
Beckie Port "From innovation to better treatments" is the title of a blog post published on 27 May 2019 by Dr Beckie Port. Beckie is Research Communications Manager at PD-MitoQUANT partner Parkinson's UK. This blog entry announces partnerships with two pan-European, IMI-funded research projects: PD-MitoQUANT and Neuronet. In it, Beckie describes how these collaborative projects aim to accelerate research and deliver new treatments for Parkinson’s. Read the full blog post here.